Characterization of [(123)I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters

Eur J Nucl Med. 1999 Aug;26(8):844-53. doi: 10.1007/s002590050458.

Abstract

Development of selective serotonin transporter (SERT) tracers for single-photon emission tomography (SPET) is important for studying the underlying pharmacology and interaction of specific serotonin reuptake site inhibitors, commonly used antidepressants, at the SERT sites in the human brain. In search of a new tracer for imaging SERT, IDAM (5-iodo-2-[[2-2-[(dimethylamino)methyl]phenyl]thio]benzyl alcohol) was developed. In vitro characterization of IDAM was carried out with binding studies in cell lines and rat tissue homogenates. In vivo binding of [(125)I]IDAM was evaluated in rats by comparing the uptakes in different brain regions through tissue dissections and ex vivo autoradiography. In vitro binding study showed that IDAM displayed an excellent affinity to SERT sites (K(i)=0.097 nM, using membrane preparations of LLC-PK(1) cells expressing the specific transporter) and showed more than 1000-fold of selectivity for SERT over norepinehrine and dopamine (expressed in the same LLC-PK(1) cells). Scatchard analysis of [(125)I]IDAM binding to frontal cortical membrane homogenates prepared from control or p-chloroamphetamine (PCA)-treated rats was evaluated. As expected, the control membranes showed a K(d) value of 0.25 nM+/-0.05 nM and a B(max) value of 272+/-30 fmol/ mg protein, while the PCA-lesioned membranes displayed a similar K(d), but with a reduced B(max) (20+/-7 fmol/ mg protein). Biodistribution of [(125)I]IDAM (partition coefficient =473; 1-octanol/buffer) in the rat brain showed a high initial uptake (2.44%dose at 2 min after i.v. injection) with the specific binding peaked at 60 min postinjection (hypothalamus-cerebellum/cerebellum =1.75). Ex vivo autoradiographs of rat brain sections (60 min after i.v. injection of [(125)I]IDAM) showed intense labeling in several regions (olfactory tubercle, lateral septal nucleus, hypothalamic and thalamic nuclei, globus pallidus, central gray, superior colliculus, substantia nigra, interpeduncular nucleus, dorsal and median raphes and locus coeruleus), which parallel known SERT density. This novel tracer has excellent characteristics for in vivo SPET imaging of SERT in the brain.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Autoradiography
  • Benzyl Alcohols* / pharmacokinetics
  • Binding Sites
  • Brain / diagnostic imaging*
  • Brain / metabolism
  • Brain Chemistry
  • Carrier Proteins / analysis*
  • Humans
  • Iodine Radioisotopes* / pharmacokinetics
  • Male
  • Membrane Glycoproteins / analysis*
  • Membrane Transport Proteins*
  • Nerve Tissue Proteins*
  • Radiopharmaceuticals / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin / analysis*
  • Serotonin Plasma Membrane Transport Proteins
  • Sulfides* / pharmacokinetics
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • 5-iodo-2-((2-((methylamino)methyl)phenyl)thio)benzyl alcohol
  • Benzyl Alcohols
  • Carrier Proteins
  • Iodine Radioisotopes
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Radiopharmaceuticals
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins
  • Slc6a4 protein, rat
  • Sulfides
  • Serotonin